Wells Fargo raised the firm’s price target on uniQure (QURE) to $80 from $65 and keeps an Overweight rating on the shares. The firm notes positive takeaways from our webinar, with favorable key opinion leader views on 3-year data and confidence in patients seeking AMT-130 and centers finding ways to offer the product. Wells continues to see blockbuster opportunity driven by compelling product profile.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE: